Dr. Patrick Soon-Shiong to Deliver Keynote at HIMSS 2020 Intelligent Health™ Pavilion
February 25 2020 - 8:00AM
Business Wire
NantHealth Chairman and CEO Will Reveal How
Advancements in AI and Machine Learning are Improving the Diagnosis
and Treatment of Cancer
NantHealth, Inc. (NASDAQ: NH), a next-generation,
evidence-based, personalized healthcare technology company,
announced today that Dr. Patrick Soon-Shiong, Chairman and CEO, has
been chosen to keynote at the Intelligent Health™ Pavilion (IHP)
during the Healthcare Information Management Systems Society
(HIMSS) 2020 Annual Conference & Exhibition in Orlando.
NantHealth is exhibiting at the show in booth #7366.
Dr. Soon-Shiong will share how AI technologies and machine
learning can improve the diagnosis and treatment of cancer. This
keynote address will highlight new clinical evidence and share
compelling patient examples, while also revealing how clinicians
can collaborate more effectively and access higher quality data to
arrive at an accurate hypotheses/diagnosis faster.
What:
“How Data is Revolutionizing Patient
Outcomes”
Who:
Dr. Patrick Soon-Shiong, Chairman and CEO
of NantHealth
When:
Tuesday, March 10 at 10:30 a.m. ET
Where:
HIMSS Annual Conference &
Exhibition
Intelligent Health Pavilion, Leadership
Theatre
Orange County Convention Center
Orlando, Florida
The session will also be available for live viewing at
https://info.nanthealth.com/himss20.
“We are excited and honored to have Dr. Patrick Soon-Shiong
share his latest scientific findings, data advancements, and
patient stories with HIMSS and the entire healthcare community,”
said Harry Pappas, Founder & CEO of the IHP. “This keynote will
be a great opportunity to hear from a well-respected and proven
healthcare and technology innovator on developments that are having
a real impact on patients and the healthcare industry at large. Dr.
Soon-Shiong and his NantHealth team are truly pioneering real
change and influence in the area of personalized medicine.”
NantHealth will also feature several use cases highlighting its
advanced data expertise in the IHP, including Eviti® Advisor, the
most comprehensive digital library of unbiased, evidence-based
oncology regimens, and NaviNet® Open, a powerful payer-provider
collaboration platform.
For more information visit,
https://info.nanthealth.com/himss20.
About NantHealth
NantHealth, a member of the NantWorks ecosystem of companies,
provides leading solutions across the continuum of care for
physicians, payers, patients and biopharmaceutical organizations.
NantHealth enables the use of cutting-edge data and technology
toward the goals of empowering clinical decision support and
improving patient outcomes. NantHealth’s comprehensive product
portfolio combines the latest technology in payer/provider
platforms that exchange information in near-real time (NaviNet and
Eviti), and molecular profiling services that combine comprehensive
DNA & RNA tumor-normal profiling with pharmacogenomics analysis
(GPS Cancer®). For more information, please visit
www.nanthealth.com or follow us on Twitter, Facebook and
LinkedIn.
Forward-Looking Statements: NantHealth
This news release contains certain statements of a
forward-looking nature relating to future events or future business
performance. Forward-looking statements can be identified by the
words “expects,” “anticipates,” “believes,” “intends,” “estimates,”
“plans,” “will,” “outlook” and similar expressions. Forward-looking
statements are based on management’s current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. Risks and uncertainties include, but are not limited to: our
ability to successfully integrate a complex learning system to
address a wide range of healthcare issues; our ability to
successfully amass the requisite data to achieve maximum network
effects; appropriately allocating financial and human resources
across a broad array of product and service offerings; raising
additional capital as necessary to fund our operations; achieving
significant commercial market acceptance for our sequencing and
molecular analysis solutions; establish relationships with, key
thought leaders or payers’ key decision makers in order to
establish GPS Cancer as a standard of care for patients with
cancer; our ability to grow the market for our Systems
Infrastructure, and applications; successfully enhancing our
Systems Infrastructure and applications to achieve market
acceptance and keep pace with technological developments; customer
concentration; competition; security breaches; bandwidth
limitations; our ability to continue our relationship with
NantOmics; our ability to obtain regulatory approvals; dependence
upon senior management; the need to comply with and meet applicable
laws and regulations; unexpected adverse events; clinical adoption
and market acceptance of GPS Cancer; and anticipated cost savings.
We undertake no obligation to update any forward-looking statement
in light of new information or future events, except as otherwise
required by law. Forward-looking statements involve inherent risks
and uncertainties, most of which are difficult to predict and are
generally beyond our control. Actual results or outcomes may differ
materially from those implied by the forward-looking statements as
a result of the impact of a number of factors, many of which are
discussed in more detail in our reports filed with the Securities
and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200225005095/en/
NantHealth Heidi Davidson Heidi@galvanizeworldwide.com
(914) 441-6862
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Aug 2024 to Sep 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Sep 2023 to Sep 2024